Enliven Therapeutics (NASDAQ:ELVN) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Enliven Therapeutics (NASDAQ:ELVN) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Enliven Therapeutics Stock Up 0.2%

Enliven Therapeutics stock opened at $29.69 on Friday. The business’s 50-day moving average price is $24.06 and its 200 day moving average price is $21.54. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -16.14 and a beta of 0.34. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.22.

Insider Buying and Selling

In other Enliven Therapeutics news, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the sale, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. The trade was a 18.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the completion of the transaction, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 233,843 shares of company stock valued at $6,145,489 in the last ninety days. Company insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Commodore Capital LP boosted its stake in Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the period. Vestal Point Capital LP raised its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc raised its holdings in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after buying an additional 418,673 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares during the period. Finally, State Street Corp grew its holdings in shares of Enliven Therapeutics by 9.1% during the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after buying an additional 87,725 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.